Global Lurbinectedin Market, By Drug Classification (3-ring heterocyclic compounds, Acetates, Alkaloids, Antineoplastics, Carbolines, Dioxolanes, Indoles, Small molecules, Spiro compounds, Tetrahydroisoquinolines), End- Users (Hospitals, Homecare, Specialty Clinics, Ambulatory Surgical Centers, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2029.
Market Analysis and Insights Global Lurbinectedin Market
The lurbinectedin market is expected to witness market growth at a rate of 45.30% in the forecast period of 2022 to 2029. Data Bridge Market Research report on lurbinectedin market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in healthcare sector globally is escalating the growth of lurbinectedin market.
Lurbinectedin, also known as PM1183, refers to an analog of the marine compound ET-736 that is isolated from the sea squirt Ecteinacidia turbinate. In this product the hydrogen atom has been replaced by a methoxy group. It is a selective inhibitor of the oncogenic transcription programs where tumors are particularly dependent. The drug inhibits oncogenic transcription in tumor-associated macrophages and declines the production of cytokines that is responsible for tumor growth.
The rise in prevalence of cancer across the globe acts as one of the major factors driving the growth of lurbinectedin market. The development of technology offering therapies for treating various cases of tumor and surge in the number of approval and uptake of premium- priced targeted therapies accelerate the market growth. The rise in company collaborations among manufacturers to develop new drugs and increase in clinical trials for the enhancement of the tumor treatments further influence the market. Additionally, rise in healthcare expenditure, change in lifestyle, increase in geriatric population and development in the biotechnology sector positively affect the lurbinectedin market. Furthermore, developments in the drugs extend profitable opportunities to the market players in the forecast period of 2022 to 2029.
On the other hand, availability of various classes of drugs is expected to obstruct the market growth. Low awareness among people is projected to challenge the lurbinectedin market in the forecast period of 2022-2029.
This lurbinectedin market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on lurbinectedin market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Global Lurbinectedin Market Scope and Market Size
The lurbinectedin market is segmented on the basis of drug classification, end-users and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of product type, the lurbinectedin market is segmented into 3-ring heterocyclic compounds, acetates, alkaloids, antineoplastics, carbolines, dioxolanes, indoles, small molecules, spiro compounds and tetrahydroisoquinolines.
- On the basis of end- users, the lurbinectedin market is segmented into hospitals, homecare, specialty clinics, ambulatory surgical centers and others.
- On the basis of distribution channel, the lurbinectedin market is segmented into hospital pharmacy, retail pharmacy and online pharmacy.
Lurbinectedin Market Country Level Analysis
The lurbinectedin market is analyzed and market size information is provided by country, drug classification, end-users and distribution channel as referenced above.
The countries covered in the global lurbinectedin market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).
North America dominates the lurbinectedin market due to the presence of developed healthcare system within the region. Asia-Pacific is expected to witness high growth during the forecast period of 2022 to 2029 because of the large population in the region.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.
Patient Epidemiology Analysis
The lurbinectedin market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.
Competitive Landscape and Lurbinectedin Market Share Analysis
The lurbinectedin market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related lurbinectedin market.
Some of the major players operating in the lurbinectedin market report are F. Hoffmann La Roche Ltd, Novartis AG, Bayer AG, GlaxoSmithKline plc, Sanofi, Amgen Inc., Merck & Co., Inc., AbbiVie Inc., Eli Lilly and Company, Bausch Health, Johnson & Johnson Services Inc., Bristol Myers Squibb and Company, AstraZeneca, Pfizer Inc., Teva Pharmaceutical Industries Ltd, and Hikma Pharmaceuticals plc, among others.
SKU-